Revolution Medicines, Inc.
RVMDHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeRevolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. Valued at $32.17B, RVMD is a large-cap name in its sector. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Market Cap
$32.17B
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
-26.84
EPS (TTM)
$-7.11
EPS (Fwd)
$-5.64
ROE
-76.7%
ROA
-37.5%
Cash
$1.91B
Total Debt
$437.3M
Free CF
-$606.4M
52W Change
274.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.91B in cash comfortably exceeding the $437.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$606.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -76.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $29.4M (2021) to $0 (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Revolution Medicines, Inc. and its sector.